Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leishmania vaccine (live attenuated)
- Development stage
- Preclinical
- Lead developer
- Gennova Biopharmaceuticals
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Gennova Biopharmaceuticals' live attenuated Leishmania vaccine is a preclinical candidate developed in collaboration with McGill University, Ohio State University, the National Institutes of Health (NIH), and Johns Hopkins University. The vaccine utilizes a genetically modified strain of the *Leishmania* parasite, specifically a centrin-deleted (*LdCen-/-*) mutant created via CRISPR-Cas9 technology. This modification allows the parasite to infect host cells and initiate an immune response but prevents it from replicating, thereby avoiding the development of clinical leishmaniasis. The program is supported by the Global Health Innovative Technology (GHIT) Fund and aims to provide long-term protection against visceral leishmaniasis through the induction of robust T-cell mediated immunity.
- Other names
- Leishmania live attenuated vaccineGennova Leishmania vaccine
Beyond the preview
Go deeper on leishmania vaccine (live attenuated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leishmania vaccine (live attenuated).